Unique ID issued by UMIN | UMIN000045874 |
---|---|
Receipt number | R000051645 |
Scientific Title | Evaluation after taking Ninjinyoeito in the treatment of post-treatment malaise associated with gynecological cancer: an prospective observational study |
Date of disclosure of the study information | 2021/10/26 |
Last modified on | 2021/10/26 16:27:17 |
Observation of the effect of Ninjinyoeito on post-treatment malaise in gynecological cancer
Observation of the effect of Ninjinyoeito on post-treatment malaise in gynecological cancer
Evaluation after taking Ninjinyoeito in the treatment of post-treatment malaise associated with gynecological cancer: an prospective observational study
Evaluation after taking Ninjinyoeito in the treatment of post-treatment malaise associated with gynecological cancer: an prospective observational study
Japan |
Malaise
Obstetrics and Gynecology |
Malignancy
NO
To investigate the improvement of post-treatment malaise in gynecological cancer patients by administration of Ninjinyoeito
Efficacy
The amount of change, rate of change of the CFS score 12 weeks after the dosage start
1) Amount and rate of change in evaluation forms (ECOG-PS, HADS, AIS, The FAACT A/CS)
2) Amount and rate of change of laboratory values measured in routine clinical care at the time of patient visit
3) Amount and rate of change in oxidative stress and antioxidant capacity
4) Associations between insomnia, loss of appetite, and anxiety and improvement in fatigue
Observational
Not applicable |
Not applicable |
Female
1) The patients complaining of fatigue and malaise
2 ) The patients who have completed gynecological cancer (cervical cancer, uterine cancer, ovarian cancer) treatment (surgical operation (pelvic lymph node dissection), chemotherapy, radiotherapy) for more than one month.
3) The patients who were prescribed with Ninjinyoeito under a doctor's diagnosis
4) The patients with documented consent
1) The patients who are regularly using other Kampo medicine.
2) The patients with stage IV malignancy
3) The patients with PS(Performance Status) of 3 or 4
4) The patients considered to have a prognosis of less than six months
5) The patients with the experience an allergy after taking any Kampo medicine
6) The patients with a remarkable digestive organ symptom
7) The patients diagnosed with major depressive disorder and undergoing prescription adjustment
8) The patients with aldosteronism, myopathy, hypokalemia, or suspected
9) The patients with hepatic dysfunction (AST>80 IU/L or ALT>80 IU/L)
10) The patients who were judged not to be included by researchers
30
1st name | Masaru |
Middle name | |
Last name | Mimura |
Keio University School of Medicine
Center for Kampo Medicine
160-8582
SHINANOMACHI 35, SHINJYUKU-KU, TOKYO JAPAN
03-5366-3824
mimura@a7.keio.jp
1st name | Yuko |
Middle name | |
Last name | Horiba |
Keio University School of Medicine
Center for Kampo Medicine
160-8582
SHINANOMACHI 35, SHINJYUKU-KU, TOKYO JAPAN
03-5366-3824
mannta217@keio.jp
Keio University School of Medicine
Center for Kampo Medicine
None
Self funding
Keio University School of Medicine
SHINANOMACHI 35, SHINJYUKU-KU, TOKYO JAPAN 160-8582
03-5363-3503
med-rinri-jimu@adst.keio.ac.jp
NO
慶應義塾大学病院(東京都)
2021 | Year | 10 | Month | 26 | Day |
Unpublished
Enrolling by invitation
2021 | Year | 08 | Month | 03 | Day |
2021 | Year | 08 | Month | 10 | Day |
2021 | Year | 08 | Month | 10 | Day |
2022 | Year | 12 | Month | 31 | Day |
CFS
ECOG-PS
HADS
AIS
The FAACT A/CS questionnaire
2021 | Year | 10 | Month | 26 | Day |
2021 | Year | 10 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051645